Zyagnum AG

What Zyagnum AG does

Zyagnum AG is a privately held German biotechnology company founded in 2007 and headquartered in Darmstadt (Gräfenhäuser Str. 26), operating with approximately 40–50 employees. The company develops and commercializes the EDIM® (Epitope Detection in Monocytes) platform, an immunological biopsy technology that detects disease-specific antigens phagocytosed by blood macrophages using flow cytometry. Its flagship commercial product is the PanTum Detect® blood test, which simultaneously measures the biomarkers TKTL1 and DNaseX (Apo10) to provide tumor-independent early indications of solid cancers in asymptomatic individuals; the company reports 95.2% sensitivity and 99.5% specificity in clinical evaluations.

Zyagnum generates revenue from one-time test sales of PanTum Detect® to hospitals, laboratories and healthcare providers, from bundled screening packages (most prominently the HanseMerkur "Krebs-Scan" supplementary insurance product combining the blood test with PET/CT and MRI imaging, launched in 2023), and from international licensing and distribution partnerships in Greater China, India, and Southeast Asia. The company's go-to-market combines B2B direct sales to clinical providers, insurance-channel distribution to reach screening consumers, and regional channel partners for cross-border commercialization. It leverages an extensive peer-reviewed publication record and university hospital collaborations (Hamburg-Eppendorf, Tübingen, Sun Yat-sen University, Beijing Hospital) to build clinical evidence.

The company holds EU medical device approval for PanTum Detect® since 2017, has active research programs extending EDIM® into prostate cancer, Alzheimer's and burnout diagnostics, and underwent a CEO transition in 2025 with Dr. Krutarth Patel assuming COO/CEO responsibilities from founder Ralf Schierl. Co-founder Dr. Johannes Coy, the discoverer of TKTL1 at DKFZ in 1995, remains active as a scientific advisor.

Name

Zyagnum AG

Legal name

Zyagnum AG

Website

https://zyagnum.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Zyagnum AG is a German biotechnology company that develops the EDIM® immunological biopsy platform and the PanTum Detect® blood test for multi-cancer early detection, selling to healthcare providers, laboratories, insurance partners (e.g., HanseMerkur), and international distributors across Europe and Asia.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics & Cancer Screening

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAAALAE

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAGADAH

Cell-Based & Potency Assays (Bioassays)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Testing & Analytical Services

SECONDARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAGADAA

Bioanalytical Testing (PK/ADA/NAb)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Testing & Analytical Services

Keywords

• Cancer screening diagnostics
• Blood-based biomarkers
• Immunological biopsy
• Early cancer detection
• Clinical diagnostic tests

Headquarters

HQ city

Pfungstadt

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. PanTum Detect® Test Sales: Sale of the PanTum Detect® cancer screening blood test to healthcare providers, laboratories, and medical facilities. The test is used in combination with imaging procedures for comprehensive cancer screening.
2. Insurance Partnership - Krebs-Scan: PanTum Detect® is offered as part of HanseMerkur's supplementary insurance product 'Krebs-Scan', combining the blood test with imaging procedures (PET/CT and MRI) and additional health services.
3. International Licensing and Partnerships: Long-term international development and cooperation partnerships in China, India and Southeast Asia for marketing PanTum Detect® and other test methods. Revenue from licensing technology and test kits to international partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Zyagnum AG develops and commercializes PanTum Detect®, a blood-based cancer screening test built on its proprietary EDIM® (Epitope Detection in Monocytes) technology platform. The test detects the enzymes TKTL1 and DNaseX (Apo10) in blood macrophages via flow cytometry, enabling tumor-independent early detection of cancer in asymptomatic phases. The product is sold to healthcare providers, laboratories, and insurance companies (notably via HanseMerkur's Krebs-Scan program), and licensed to international distribution partners.

Differentiator

Problem solved

Functional benefit

Brands

• PanTum Detect®: Cancer screening blood test for the early detection of tumors based on EDIM® Technology, detecting the enzymes TKTL1 and DNaseX (Apo10) in blood macrophages.

Products and services

• PanTum Detect® A blood-based cancer screening test that uses the proprietary EDIM® (Epitope Detection in Monocytes) technology to detect the enzymes TKTL1 and DNaseX (Apo10) in blood macrophages. Provides tumor-independent early indication of multiple solid tumor cancer types in asymptomatic phases, intended for use by healthcare providers and laboratories as a screening test preceding confirmatory imaging (PET/CT, MRI).
• Krebs-Scan Insurance Program A two-stage cancer screening program offering combining PanTum Detect® blood test with imaging diagnostics (PET/CT and MRI), telemedical care, and hospital benefits. Distributed as a HanseMerkur supplementary insurance product to provide comprehensive cancer early detection not covered by statutory health insurance.

Quantifiable outcome

• 95.2% sensitivity and 99.5% specificity for cancer detection
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

15 partnerships are on record, tiered core, major and minor.

• IMB (HongKong) International Medical and Bioscience Ltd.coreChannel Partner/ Reseller/ Distributor · 1 January 2018Long-term development and cooperation partnership for marketing PanTum Detect® in Hong Kong and surrounding markets.
• IMB (China) Medical and Biotechnologies Co. Ltd.coreChannel Partner/ Reseller/ Distributor · 1 January 2018Long-term development and cooperation partnership for marketing PanTum Detect® and other test methods in China.
• Medidect Holding Pte. Ltd.majorChannel Partner/ Reseller/ Distributor · 1 January 2018Cooperation partnership for distribution of PanTum Detect® in Southeast Asia markets.
• Millenium Oncology India Private LimitedmajorChannel Partner/ Reseller/ Distributor · 1 January 2018Long-term development and cooperation partnership for marketing PanTum Detect® in India.
• University hospital Hamburg-EppendorfcoreStrategic or Co-development PartnerResearch partnership for large-scale screening study with over 5,000 asymptomatic participants investigating the combination of PanTum Detect® and subsequent imaging diagnostics (PET/CT and MRI). The study demonstrated the effectiveness of the two-stage cancer screening approach.
• University hospital TübingencoreStrategic or Co-development PartnerResearch partnership conducting studies on PanTum Detect® for pediatric cancers including neuroblastoma and rhabdomyosarcoma. Published studies in British Journal of Cancer and Biomedicines demonstrated high detection rates (94.7% and 96.5% respectively).
• Sun Yat-sen University, GuangzhoucoreStrategic or Co-development PartnerResearch partnership conducting studies on Apo10 and TKTL1 biomarkers for early detection of breast cancer, lung cancer, and cervical cancer. Published multiple peer-reviewed studies demonstrating diagnostic value of the markers in early-stage cancer detection.
• Beijing Hospital, ChinaminorStrategic or Co-development PartnerResearch partnership for validation of EDIM® Technology and PanTum Detect® in Chinese patient populations.
• Millenium Cancer Center, New DelhiminorStrategic or Co-development PartnerResearch partnership for cancer diagnostics research and development in the Indian market.
• HanseMerkur VersicherungsgruppecoreChannel Partner/ Reseller/ DistributorInsurance partnership for integration of PanTum Detect® into the 'Krebs-Scan' supplementary insurance product. This two-stage cancer screening program combines the blood test with state-of-the-art imaging procedures (PET/CT, MRI) and additional health services including telemedical care and hospital benefits.
• JEMO TRADING spol. s.r.o.minorChannel Partner/ Reseller/ DistributorCooperation partnership for distribution and development activities.
• R&V Intertrade Co., Ltd.minorChannel Partner/ Reseller/ DistributorCooperation partnership for international trade and distribution.
• RMDM Diagnostics LimitedminorChannel Partner/ Reseller/ DistributorCooperation partnership for diagnostic solutions distribution.
• KomProdService LLCminorChannel Partner/ Reseller/ DistributorCooperation partnership for product distribution and services.
• MD Solutions DOOminorChannel Partner/ Reseller/ DistributorCooperation partnership for medical diagnostic solutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Guardant Health: Guardant offers blood-based oncology diagnostics (Guardant360, Reveal) for tumor profiling and MRD, with emerging MCED programs. Comparable to Zyagnum in blood-based cancer detection and in flow-cytometry-adjacent laboratory infrastructure.
• Natera: Natera offers Signatera (MRD) and other blood-based oncology tests. Comparable to Zyagnum as a developer and commercializer of proprietary blood-based oncology diagnostics sold to hospitals and laboratories.
• Exact Sciences: Through Cologuard and the acquired Thrive Earlier Detection (CancerSEEK), Exact Sciences is the most advanced commercial player in non-invasive cancer screening. Comparable to Zyagnum as a blood/stool-based cancer screening company selling to clinicians, payers, and consumers at population scale.

Regional players

• Singlera Genomics: Singlera is a China-based company developing blood-based multi-cancer early detection tests (e.g., PanSeer). Comparable to Zyagnum as a regional MCED competitor and potential China-market rival to the IMB partnership distribution.
• Burning Rock Biotech: Burning Rock is a China-based oncology diagnostics company specializing in NGS-based cancer testing. Comparable as a regional oncology diagnostics peer operating in one of Zyagnum's key international partnership markets (China via IMB).
• AnchorDx: AnchorDx is a China-based liquid biopsy company developing blood-based cancer screening tests. Comparable as a regional peer operating in one of Zyagnum's international distributor markets and pursuing similar early-detection use cases.

Emerging players

• Freenome: Freenome is developing a blood-based multi-cancer screening test using multiomics (cfDNA, proteins). Directly comparable to PanTum Detect® as a blood-based MCED entrant targeting the asymptomatic screening market.

Direct peers

• Oncimmune: Oncimmune's EarlyCDT is a blood-based test for early cancer detection using autoantibodies. Closely comparable to PanTum Detect® as a small-cap European-headquartered cancer-screening blood test company targeting early-stage detection.
• GRAIL: GRAIL's Galleri is the leading multi-cancer early-detection (MCED) blood test, directly comparable to PanTum Detect® as a single-sample screening assay intended to detect multiple cancer types before symptoms — though GRAIL uses methylation-based cell-free DNA rather than macrophage antigens.
• VolitionRx: VolitionRx is developing the Nu.Q® blood-based cancer diagnostic platform. Comparable to Zyagnum as a small-cap, single-platform, blood-based cancer diagnostics company with a CE-marked assay pursuing multi-cancer applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/zyagnum-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zyagnum AG